Dbv Technologies SA

DBVT · NYSE

$9.75+$0.07 (+0.72%)TodayMarket closed · Oct 23, 4:30 PM ET

Prev close $9.68

DBVT analyst rating

BuyConsensus of 4 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy4
Hold0
Underperform0
Sell0

12-month price target · 6 analysts

Average $29.40 (+201.5% upside)

Low: $5.57
Now: $9.75
High: $57.92

Upgrades and downgrades

The latest rating actions, newest first

DBVT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Citizens	Jun 30, 2026	Maintains	Market Outperform	$47.00 → $55.00	46%
Guggenheim	May 4, 2026	Maintains	Buy	$51.00	49%
Citizens	May 1, 2026	Maintains	Market Outperform	$47.00 → $55.00	46%
Citizens	Mar 27, 2026	Maintains	Market Outperform	$45.00 → $47.00	46%
Guggenheim	Mar 27, 2026	Maintains	Buy	$51.00	49%
HC Wainwright & Co.	Dec 17, 2025	Maintains	Buy	$35.00 → $40.00	52%
Cantor Fitzgerald	Dec 17, 2025	Maintains	Overweight	$42.00 → $48.00	41%
Citizens	Dec 17, 2025	Maintains	Market Outperform	$21.00 → $45.00	46%
Guggenheim	Dec 17, 2025	Maintains	Buy	$35.00 → $51.00	49%
HC Wainwright & Co.	Dec 15, 2025	Maintains	Buy	$20.00 → $35.00	52%

The case for and against

Updated Oct 21, 2026

Bull case

DBV Technologies is supported by a differentiated, non-invasive Viaskin Peanut patch that delivers a micro-dose of peanut protein through intact skin, potentially lowering systemic exposure and anaphylaxis risk versus oral immunotherapy. Its lead program is advancing through clear regulatory milestones, with BLA submissions for children aged 4–7 in 1H26 and toddlers in 2H26, while the positive VITESSE readout and ongoing COMFORT-TODDLER study strengthen the clinical and regulatory case. Financially, the company reported a 1Q26 net loss of about $47.4 million, held about $229 million in cash, and expects runway into 2Q27, giving it time to execute on a potentially commercial-ready launch and expand into infants through THRIVE.

Bear case

DBV Technologies is facing substantial clinical and regulatory uncertainty, with delayed BLA submissions in children and toddlers, adverse findings in COMFORT-TODDLER, and dependence on VITESSE and a later confirmatory trial to support approvals across age groups. The company also remains exposed to meaningful financial risk, as it is expected to continue incurring net losses at least until commercialization and likely through the early launch phase, increasing the chance of additional capital raises with dilutive impact. Commercially, Viaskin Peanut’s variable desensitization leaves patients uncertain about real-world protection, while strict avoidance remains necessary and new competitors could further pressure adoption.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.